CA2041246A1 - Composition et traitement a base de peptides biologiquement actifs et d'agents antiparasitaires ou antifongiques - Google Patents
Composition et traitement a base de peptides biologiquement actifs et d'agents antiparasitaires ou antifongiquesInfo
- Publication number
- CA2041246A1 CA2041246A1 CA002041246A CA2041246A CA2041246A1 CA 2041246 A1 CA2041246 A1 CA 2041246A1 CA 002041246 A CA002041246 A CA 002041246A CA 2041246 A CA2041246 A CA 2041246A CA 2041246 A1 CA2041246 A1 CA 2041246A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- amino acid
- composition
- protein
- hydrophobic amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 120
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 229940121375 antifungal agent Drugs 0.000 title claims abstract description 21
- 239000003429 antifungal agent Substances 0.000 title claims abstract description 21
- 239000003096 antiparasitic agent Substances 0.000 title claims abstract description 10
- 229940125687 antiparasitic agent Drugs 0.000 title claims abstract description 8
- 102000004196 processed proteins & peptides Human genes 0.000 title description 15
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 241000233866 Fungi Species 0.000 claims abstract description 7
- 244000045947 parasite Species 0.000 claims abstract description 7
- 150000001413 amino acids Chemical class 0.000 claims description 50
- 230000002209 hydrophobic effect Effects 0.000 claims description 29
- 230000007935 neutral effect Effects 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 12
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 7
- 108060003100 Magainin Proteins 0.000 claims description 7
- 229960004125 ketoconazole Drugs 0.000 claims description 6
- 229960001624 pentamidine isethionate Drugs 0.000 claims 2
- YBVNFKZSMZGRAD-UHFFFAOYSA-N pentamidine isethionate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 YBVNFKZSMZGRAD-UHFFFAOYSA-N 0.000 claims 2
- 229960000771 propamidine isethionate Drugs 0.000 claims 2
- WSOSYBUSMXEYDO-UHFFFAOYSA-N propamidine isethionate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCOC1=CC=C(C(N)=N)C=C1 WSOSYBUSMXEYDO-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 description 41
- 239000002253 acid Substances 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 26
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 17
- 150000007513 acids Chemical class 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 101800004819 PGLa Proteins 0.000 description 5
- 241000521257 Hydrops Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BZACJASHKPPTKX-UHFFFAOYSA-N 3-bromo-4-[3-(2-bromo-4-carbamimidoylphenoxy)propoxy]benzenecarboximidamide;2-hydroxyethanesulfonic acid Chemical compound OCCS(O)(=O)=O.BrC1=CC(C(=N)N)=CC=C1OCCCOC1=CC=C(C(N)=N)C=C1Br BZACJASHKPPTKX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000004215 spore Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000224422 Acanthamoeba Species 0.000 description 2
- 241000224489 Amoeba Species 0.000 description 2
- 241000224421 Heterolobosea Species 0.000 description 2
- 210000003001 amoeba Anatomy 0.000 description 2
- 230000002141 anti-parasite Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- WTFXJFJYEJZMFO-UHFFFAOYSA-N propamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCOC1=CC=C(C(N)=N)C=C1 WTFXJFJYEJZMFO-UHFFFAOYSA-N 0.000 description 2
- 229960003761 propamidine Drugs 0.000 description 2
- JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 1
- VUFSCSMOKMPDLE-UHFFFAOYSA-N 1,1,3,3-tetraethoxy-2,2-dimethylpropane Chemical compound CCOC(OCC)C(C)(C)C(OCC)OCC VUFSCSMOKMPDLE-UHFFFAOYSA-N 0.000 description 1
- 241000224423 Acanthamoeba castellanii Species 0.000 description 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
- RRNIZKPFKNDSRS-UHFFFAOYSA-N Bensulide Chemical compound CC(C)OP(=S)(OC(C)C)SCCNS(=O)(=O)C1=CC=CC=C1 RRNIZKPFKNDSRS-UHFFFAOYSA-N 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 101100335897 Caenorhabditis elegans gly-9 gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 108050004290 Cecropin Proteins 0.000 description 1
- 241000543381 Cliftonia monophylla Species 0.000 description 1
- 241000518994 Conta Species 0.000 description 1
- 101100072702 Drosophila melanogaster defl gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101100165118 Homo sapiens BACE2 gene Proteins 0.000 description 1
- 241000271915 Hydrophis Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 101100189356 Mus musculus Papolb gene Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000208474 Protea Species 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003816 axenic effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003812 trophozoite Anatomy 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US515248 | 1983-07-19 | ||
| US51524890A | 1990-04-27 | 1990-04-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2041246A1 true CA2041246A1 (fr) | 1991-10-28 |
Family
ID=24050570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002041246A Abandoned CA2041246A1 (fr) | 1990-04-27 | 1991-04-25 | Composition et traitement a base de peptides biologiquement actifs et d'agents antiparasitaires ou antifongiques |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0526570A4 (fr) |
| JP (1) | JPH05507077A (fr) |
| CA (1) | CA2041246A1 (fr) |
| WO (1) | WO1991016918A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593866A (en) * | 1992-08-21 | 1997-01-14 | The University Of British Columbia | Cationic peptides and method for production |
| US5733872A (en) * | 1993-03-12 | 1998-03-31 | Xoma Corporation | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
| US6057291A (en) | 1995-06-02 | 2000-05-02 | University Of British Columbia | Antimicrobial cationic peptides |
| WO1997008199A2 (fr) | 1995-08-23 | 1997-03-06 | University Of British Columbia | Peptides cationiques antimicrobiens et procedes de reconnaissance de ceux-ci |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4543252A (en) * | 1982-01-21 | 1985-09-24 | The Regents Of The University Of California | Cationic oligopeptides having microbicidal activity |
| US4810777A (en) * | 1987-03-04 | 1989-03-07 | The United States Of America As Represented By The Department Of Health And Human Services | Antimicrobial compounds |
-
1991
- 1991-04-24 EP EP19910909220 patent/EP0526570A4/en not_active Ceased
- 1991-04-24 JP JP91508676A patent/JPH05507077A/ja active Pending
- 1991-04-24 WO PCT/US1991/002825 patent/WO1991016918A1/fr not_active Application Discontinuation
- 1991-04-25 CA CA002041246A patent/CA2041246A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0526570A4 (en) | 1993-04-21 |
| JPH05507077A (ja) | 1993-10-14 |
| EP0526570A1 (fr) | 1993-02-10 |
| WO1991016918A1 (fr) | 1991-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0667871A4 (fr) | Compositions peptidiques amphiphiles biologiquement actives et utilisations desdites compositions. | |
| CA2086111A1 (fr) | Compositions a base de peptides bioactifs et utilisations | |
| CA2137087A1 (fr) | Peptides a action biologique substitues en position n-terminale | |
| CA2107674A1 (fr) | Nouvelles compositions peptidiques et leur utilisation | |
| US5217956A (en) | Composition and treatment with biologically active peptides and certain anions | |
| CA2035959A1 (fr) | Compositions peptidiques et leurs utilisations | |
| JPH08502754A (ja) | 新規の生物学的活性ペプチドおよびその利用 | |
| CA2083594A1 (fr) | Compositions peptidiques biologiquement actives et leurs utilisations | |
| US5208220A (en) | Composition and treatment with biologically active peptides and antibiotics which inhibit DNA gyrase | |
| US9839669B2 (en) | Antiviral agent comprising recombinant mistletoe lectins | |
| CA2041246A1 (fr) | Composition et traitement a base de peptides biologiquement actifs et d'agents antiparasitaires ou antifongiques | |
| CA2111214A1 (fr) | Composition et traitement avec peptides biologiquement actifs ayant des substitutions c-terminales | |
| CA2125494A1 (fr) | Traitement a l'aide d'une composition a base de peptides et d'agents de chelation biologiquement actifs | |
| WO2008089234A2 (fr) | Polypeptides naturels pour hygiène bucco-dentaire | |
| EP0441832B1 (fr) | Composition et traitement a l'aide et peptides a activite biologique et certains anions | |
| CA2040510A1 (fr) | Composition et traitement faisant appel a des peptides biologiquement actifs et a des cations toxiques | |
| US6348445B1 (en) | Biologically active peptides with reduced toxicity in animals and a method for preparing same | |
| AU693518B2 (en) | Ion-channel forming amphiphilic peptides having n-terminal modifications | |
| JP3002725B2 (ja) | 線維芽細胞増殖因子関連ペプチドからなる医薬組成物 | |
| KR20230063347A (ko) | 항바이러스성 펩토이드 조성물 | |
| US5254537A (en) | Composition and treatment with peptide combinations | |
| EP0455719A4 (en) | Composition and treatment with peptide combinations | |
| CA2042468A1 (fr) | Compositions et traitement de peptides biologiquement actifs contenant des residus d'acides d-amines | |
| Smeijsters et al. | Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl) adenine in Plasmodium berghei-infected mice | |
| CZ286953B6 (en) | Medicament for blocking retroviral infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |